Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease,...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of AVTX is 33 and suggests 110% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell